David Michelson, MD | Psychiatrist.com

Original Research

Randomized Controlled Study of the Histamine H3 Inverse Agonist MK-0249 in Adult Attention-Deficit/Hyperactivity Disorder

July 15, 2012

W. Joseph Herring, Timothy E. Wilens, Lenard A. Adler, et al

Original Research

Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study

April 16, 2007

David Michelson, Lenard A. Adler, Jay D. Amsterdam, et al

Original Research

Atomoxetine and Adult Attention-Deficit/Hyperactivity Disorder: The Effects of Comorbidity.

March 15, 2006

Thomas J. Spencer, Stephen V. Faraone, David Michelson, et al

Original Research

Long-Term, Open-Label Study of the Safety and Efficacy of Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder: An Interim Analysis

March 15, 2005

Lenard A. Adler, Thomas J. Spencer, Denái R. Milton, et al

Original Research

Long-Term Treatment Outcomes of Depression With Associated Anxiety: Efficacy of Continuation Treatment With Fluoxetine

March 1, 2004

Melissa J. Joliat, Mark E. Schmidt, Maurizio Fava, et al

Article

Drug Development Process for a Product with a Primary Pediatric Indication

October 1, 2002

Albert J. Allen, David Michelson

Article

Drug Development Process for a Product with a Primary Pediatric Indication

October 1, 2002

Albert J. Allen, David Michelson

Original Research

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

June 30, 1999

John Zajecka, Jay D. Amsterdam, Frederic M. Quitkin, et al

Letter to the Editor

Comparing the Efficacy and Safety of Fluoxetine and Venlafaxine in Outpatient Depression

May 1, 1999

David Michelson